Mediwound Ltd Ord Sh (MDWD) 8.03 $MDWD
MediWound's NexoBrid(R) Receives Reimbursement in Italy
GlobeNewswire - Tue Jun 07, 6:00AM CDT
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that the Board of the Italian Drug Agency (AIFA) has approved the pricing and reimbursement conditions for NexoBrid for the removal of eschar in adults with deep partial and full-thickness thermal burns.
MDWD: 8.03 (+0.06)
MediWound to Present at Jefferies 2016 Healthcare Conference
GlobeNewswire - Wed Jun 01, 6:00AM CDT
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that Company management will participate at Jefferies 2016 Healthcare Conference taking place from June 7-10, 2016 in New York City. Gal Cohen, President and Chief Executive Officer of MediWound, will deliver the Company's presentation on Wednesday, June 8th at 10:30 a.m. Eastern time.
MDWD: 8.03 (+0.06)
Data Published in Bone & Joint Research Supports MediWound's Bromelain-Based Enzyme for the Release of Dupuytren's Contracture
GlobeNewswire - Tue May 31, 6:30AM CDT
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that a comprehensive review of injectable bromelain solution (IBS, or MWPC003) for the treatment of Dupuytren's contracture (DC) was published in the May 2016 edition of the peer-reviewed journal Bone & Joint Research. The online version of the review article, "A new bromelain-based enzyme for the release of Dupuytren's contracture," can be accessed here.
MDWD: 8.03 (+0.06)
MediWound's NexoBrid(R) Highlighted in "Best Oral Presentation" at the British Burn Association 49th Annual Conference and Scientific Meeting
GlobeNewswire - Thu May 19, 6:00AM CDT
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that an abstract highlighting the merits of NexoBridin the direct assessment of burn severity was selected as "Best Oral Presentation" at the British Burn Association's (BBA) 49 Annual Conference and Scientific Meeting. The BBA conference was held in Newcastle, England May 11-13, 2016, and the presentation, titled "Burn Depth Assessment: Laser Doppler Imaging (LDI) vs. Enzymatic Debridement," was delivered by Dr. Hendrik Hoeksema, Department of Plastic Surgery, University Ziekenhuis Hospital, Gent Belgium.
MDWD: 8.03 (+0.06)
MediWound's NexoBrid(R) to be Highlighted in Presentations at the American Burn Association 48th Annual Meeting
GlobeNewswire - Mon May 02, 6:00AM CDT
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that 11 presentations highlighting the positive results achieved by clinicians using NexoBrid as an effective enzymatic debridement for severe burns will be presented during the American Burn Association (ABA) 48 Annual Meeting, taking place May 3-6, 2016 at Caesars Palace in Las Vegas.
MDWD: 8.03 (+0.06)
MediWound's NexoBrid to be Available in Japan through Kaken Pharmaceuticals Co., Ltd.
GlobeNewswire - Tue Apr 26, 6:02AM CDT
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces the signing of an agreement granting Kaken Pharmaceuticals Co., Ltd. (KAKEN) (Tokyo Stock Exchange:4521) exclusive rights to develop and distribute NexoBrid in Japan for the treatment of severe burns.
MDWD: 8.03 (+0.06)
MediWound Reports First Quarter 2016 Financial Results
GlobeNewswire - Thu Apr 21, 6:01AM CDT
MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, reports financial results for the three months ended March 31, 2016.
MDWD: 8.03 (+0.06)
MediWound to Host First Quarter 2016 Financial Results Conference Call on April 21, 2016 at 8:30 a.m. Eastern Time
GlobeNewswire - Thu Apr 14, 6:00AM CDT
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announces that the Company will release financial results for the three months ended March 31, 2016, at 7:00 a.m. Eastern time on April 21, 2016.
MDWD: 8.03 (+0.06)
Top-Line Results from Phase 2 Study with MediWound's EscharEx to Treat Chronic Wounds Will be Presented at the Symposium on Advanced Wound Care Spring 2016
GlobeNewswire - Fri Apr 08, 6:00AM CDT
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that top-line data from a multicenter Phase 2 clinical study of the Company's EscharEx to treat chronic wounds will be presented in the Late-Breaking Session at the Spring Symposium on Advanced Wound Care (SAWC) 2016 taking place April 13-17, 2016 in Atlanta.
MDWD: 8.03 (+0.06)
MediWound to Present at Needham & Company's 15th Annual Healthcare Conference
GlobeNewswire - Wed Apr 06, 6:00AM CDT
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that Company management will participate at Needham & Company's 15th Annual Healthcare Conference taking place from April 12-13, 2016 in New York City. Gal Cohen, President and Chief Executive Officer, will deliver MediWound's presentation on Tuesday, April 12th at 3:00 p.m. Eastern time.
MDWD: 8.03 (+0.06)
MediWound to Present at the 36th Annual Cowen Health Care Conference
GlobeNewswire - Mon Mar 07, 6:00AM CST
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that Company management will participate at the 36 Annual Cowen Healthcare Conference taking place from March 7-9 at the Boston Marriot Copley Place in Boston. Gal Cohen, President and Chief Executive Officer, will deliver MediWound's presentation on Wednesday, March 9 at 9:20 a.m. Eastern time, with a breakout to follow at 10:00 a.m. Eastern time.
MDWD: 8.03 (+0.06)
MediWound's EscharEx(R) Meets Primary Endpoint in Second Phase 2 Clinical Trial for the Debridement of Chronic and Hard-to-Heal Wounds
GlobeNewswire - Tue Feb 02, 3:54PM CST
Data demonstrate strong results in diabetic foot ulcers and venous leg ulcers
MDWD: 8.03 (+0.06)
MediWound Reports 2015 Fourth Quarter and Full Year Financial Results
GlobeNewswire - Mon Jan 25, 6:00AM CST
MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, reports financial results for the three and 12 months ended December 31, 2015.
MDWD: 8.03 (+0.06)
MediWound to Host Fourth Quarter and Year End 2015 Financial Results Conference Call on January 25, 2016 at 8:30 a.m. Eastern Time
GlobeNewswire - Tue Jan 19, 7:00AM CST
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release financial results for the three and twelve months ended December 31, 2015, at 7:00 a.m. Eastern time on January 25, 2016.
MDWD: 8.03 (+0.06)
MediWound's NexoBrid Highlighted in Presentations at the 4th International Conference on Healthcare System Preparedness and Response to Emergencies and Disasters
GlobeNewswire - Mon Jan 11, 7:30AM CST
MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that two presentations highlighting NexoBrid's potential role in managing Mass Casualty Incidence will be presented at the 4th International Conference on Preparedness and Response of Healthcare Systems to Emergencies and Disasters (IPRED IV), being held January 10 - 13, 2016 in Tel Aviv.
MDWD: 8.03 (+0.06)
Diabetic Foot Ulcers - Pipeline Review 2015
M2 - Wed Jan 06, 4:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/n92r2c/diabetic_foot) has announced the addition of the "Diabetic Foot Ulcers - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Foot Ulcers, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Foot Ulcers and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies. - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Develop strategic initiatives by understanding the focus areas of leading companies. - Identify and understand important and diverse types of therapeutics under development for Diabetic Foot Ulcers. - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Diabetic Foot Ulcers pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned: - Adocia - Aprogen, Inc. - Bayer AG - CardioVascular BioTherapeutics, Inc. - Celgene Corporation - CoDa Therapeutics, Inc. - CytoTools AG - Dipexium Pharmaceuticals LLC - EyeGene, Inc. - FirstString Research, Inc. - GlaxoSmithKline Plc - Human Stem Cells Institute - Innovaxis - Izun Pharmaceuticals Corporation - Karyopharm Therapeutics, Inc. - Lytix Biopharma AS - MediaPharma s.r.l. - MediWound Ltd. - NovaLead Pharma Pvt. Ltd. - Oneness Biotech Co., Ltd. - Osiris Therapeutics, Inc. - Plurogen Therapeutics, Inc. - Sanofi - Stratatech Corporation - TechnoPhage SA - TGV-Laboratories - Theravasc, Inc. - Tissue Med Biosciences - USV Limited For more information visit http://www.researchandmarkets.com/research/n9...betic_foot
DPRX: 10.39 (+0.07), OSIR: 5.47 (+0.27), MDWD: 8.03 (+0.06), GSK: 42.36 (+0.60), KPTI: 7.97 (+0.29), CELGZ: 1.45 (+0.01)
MediWound Ltd. Industry - Product Pipeline Review 2015 | Acute Market Reports
M2 - Tue Dec 22, 3:55AM CST
Acute Market Reports's, 'MediWound Ltd. - Product Pipeline Review - 2015', provides an overview of the MediWound Ltd.'s pharmaceutical research and development focus.
MDWD: 8.03 (+0.06)
Global Burns Therapeutics Pipeline Review 2015
M2 - Thu Dec 03, 7:57AM CST
Research and Markets (http://www.researchandmarkets.com/research/phkvtr/burns_pipeline) has announced the addition of the "Burns - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Burns, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Burns and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adocia - AlgiPharma AS - Biogenomics Limited - Birken AG - CytoTools AG - Destiny Pharma Limited - HanAll Biopharma Co., Ltd. - Kuros Biosurgery AG - MediWound Ltd. - Novan, Inc. - Novartis AG - Pherecydes Pharma SA - Phosphagenics Limited - Se-cure Pharmaceuticals Ltd. - Stratatech Corporation - USV Limited - Vida Therapeutics Inc. - Xiber Science GmbH For more information visit http://www.researchandmarkets.com/research/ph...s_pipeline
MDWD: 8.03 (+0.06), NVS: 80.49 (+0.78)
MediWound to Present at the Oppenheimer 26th Annual Healthcare Conference
GlobeNewswire - Tue Dec 01, 8:45AM CST
MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn and wound management, announces that Company management will participate at the Oppenheimer 26 Annual Healthcare Conference taking place from December 8-9 at the Westin Grand Central Hotel in New York City. Gal Cohen, President and Chief Executive Officer, will deliver MediWound's presentation on Tuesday, December 8 at 1:35 p.m. Eastern time.
MDWD: 8.03 (+0.06)
MediWound Appoints Aharon Yaari to Its Board of Directors
GlobeNewswire - Tue Dec 01, 6:00AM CST
MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn and wound management, announces today the appointment of Aharon Yaari to the Company's Board of Directors. With this change, the Company's Board of Directors increases to seven members, while the composition of the Board's committees remain unchanged.
MDWD: 8.03 (+0.06)
MediWound's NexoBrid(R) Receives Reimbursement in Italy
GlobeNewswire - Tue Jun 07, 6:00AM CDT
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that the Board of the Italian Drug Agency (AIFA) has approved the pricing and reimbursement conditions for NexoBrid for the removal of eschar in adults with deep partial and full-thickness thermal burns.
MDWD: 8.03 (+0.06)
MediWound to Present at Jefferies 2016 Healthcare Conference
GlobeNewswire - Wed Jun 01, 6:00AM CDT
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that Company management will participate at Jefferies 2016 Healthcare Conference taking place from June 7-10, 2016 in New York City. Gal Cohen, President and Chief Executive Officer of MediWound, will deliver the Company's presentation on Wednesday, June 8th at 10:30 a.m. Eastern time.
MDWD: 8.03 (+0.06)
Data Published in Bone & Joint Research Supports MediWound's Bromelain-Based Enzyme for the Release of Dupuytren's Contracture
GlobeNewswire - Tue May 31, 6:30AM CDT
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that a comprehensive review of injectable bromelain solution (IBS, or MWPC003) for the treatment of Dupuytren's contracture (DC) was published in the May 2016 edition of the peer-reviewed journal Bone & Joint Research. The online version of the review article, "A new bromelain-based enzyme for the release of Dupuytren's contracture," can be accessed here.
MDWD: 8.03 (+0.06)
MediWound's NexoBrid(R) Highlighted in "Best Oral Presentation" at the British Burn Association 49th Annual Conference and Scientific Meeting
GlobeNewswire - Thu May 19, 6:00AM CDT
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that an abstract highlighting the merits of NexoBridin the direct assessment of burn severity was selected as "Best Oral Presentation" at the British Burn Association's (BBA) 49 Annual Conference and Scientific Meeting. The BBA conference was held in Newcastle, England May 11-13, 2016, and the presentation, titled "Burn Depth Assessment: Laser Doppler Imaging (LDI) vs. Enzymatic Debridement," was delivered by Dr. Hendrik Hoeksema, Department of Plastic Surgery, University Ziekenhuis Hospital, Gent Belgium.
MDWD: 8.03 (+0.06)
MediWound's NexoBrid(R) to be Highlighted in Presentations at the American Burn Association 48th Annual Meeting
GlobeNewswire - Mon May 02, 6:00AM CDT
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that 11 presentations highlighting the positive results achieved by clinicians using NexoBrid as an effective enzymatic debridement for severe burns will be presented during the American Burn Association (ABA) 48 Annual Meeting, taking place May 3-6, 2016 at Caesars Palace in Las Vegas.
MDWD: 8.03 (+0.06)
MediWound's NexoBrid to be Available in Japan through Kaken Pharmaceuticals Co., Ltd.
GlobeNewswire - Tue Apr 26, 6:02AM CDT
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces the signing of an agreement granting Kaken Pharmaceuticals Co., Ltd. (KAKEN) (Tokyo Stock Exchange:4521) exclusive rights to develop and distribute NexoBrid in Japan for the treatment of severe burns.
MDWD: 8.03 (+0.06)
MediWound Reports First Quarter 2016 Financial Results
GlobeNewswire - Thu Apr 21, 6:01AM CDT
MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, reports financial results for the three months ended March 31, 2016.
MDWD: 8.03 (+0.06)
MediWound to Host First Quarter 2016 Financial Results Conference Call on April 21, 2016 at 8:30 a.m. Eastern Time
GlobeNewswire - Thu Apr 14, 6:00AM CDT
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announces that the Company will release financial results for the three months ended March 31, 2016, at 7:00 a.m. Eastern time on April 21, 2016.
MDWD: 8.03 (+0.06)
Top-Line Results from Phase 2 Study with MediWound's EscharEx to Treat Chronic Wounds Will be Presented at the Symposium on Advanced Wound Care Spring 2016
GlobeNewswire - Fri Apr 08, 6:00AM CDT
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that top-line data from a multicenter Phase 2 clinical study of the Company's EscharEx to treat chronic wounds will be presented in the Late-Breaking Session at the Spring Symposium on Advanced Wound Care (SAWC) 2016 taking place April 13-17, 2016 in Atlanta.
MDWD: 8.03 (+0.06)
MediWound to Present at Needham & Company's 15th Annual Healthcare Conference
GlobeNewswire - Wed Apr 06, 6:00AM CDT
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that Company management will participate at Needham & Company's 15th Annual Healthcare Conference taking place from April 12-13, 2016 in New York City. Gal Cohen, President and Chief Executive Officer, will deliver MediWound's presentation on Tuesday, April 12th at 3:00 p.m. Eastern time.
MDWD: 8.03 (+0.06)
MediWound to Present at the 36th Annual Cowen Health Care Conference
GlobeNewswire - Mon Mar 07, 6:00AM CST
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that Company management will participate at the 36 Annual Cowen Healthcare Conference taking place from March 7-9 at the Boston Marriot Copley Place in Boston. Gal Cohen, President and Chief Executive Officer, will deliver MediWound's presentation on Wednesday, March 9 at 9:20 a.m. Eastern time, with a breakout to follow at 10:00 a.m. Eastern time.
MDWD: 8.03 (+0.06)
MediWound's EscharEx(R) Meets Primary Endpoint in Second Phase 2 Clinical Trial for the Debridement of Chronic and Hard-to-Heal Wounds
GlobeNewswire - Tue Feb 02, 3:54PM CST
Data demonstrate strong results in diabetic foot ulcers and venous leg ulcers
MDWD: 8.03 (+0.06)
MediWound Reports 2015 Fourth Quarter and Full Year Financial Results
GlobeNewswire - Mon Jan 25, 6:00AM CST
MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, reports financial results for the three and 12 months ended December 31, 2015.
MDWD: 8.03 (+0.06)
MediWound to Host Fourth Quarter and Year End 2015 Financial Results Conference Call on January 25, 2016 at 8:30 a.m. Eastern Time
GlobeNewswire - Tue Jan 19, 7:00AM CST
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release financial results for the three and twelve months ended December 31, 2015, at 7:00 a.m. Eastern time on January 25, 2016.
MDWD: 8.03 (+0.06)
MediWound's NexoBrid Highlighted in Presentations at the 4th International Conference on Healthcare System Preparedness and Response to Emergencies and Disasters
GlobeNewswire - Mon Jan 11, 7:30AM CST
MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that two presentations highlighting NexoBrid's potential role in managing Mass Casualty Incidence will be presented at the 4th International Conference on Preparedness and Response of Healthcare Systems to Emergencies and Disasters (IPRED IV), being held January 10 - 13, 2016 in Tel Aviv.
MDWD: 8.03 (+0.06)
Diabetic Foot Ulcers - Pipeline Review 2015
M2 - Wed Jan 06, 4:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/n92r2c/diabetic_foot) has announced the addition of the "Diabetic Foot Ulcers - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Foot Ulcers, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Foot Ulcers and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies. - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Develop strategic initiatives by understanding the focus areas of leading companies. - Identify and understand important and diverse types of therapeutics under development for Diabetic Foot Ulcers. - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Diabetic Foot Ulcers pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned: - Adocia - Aprogen, Inc. - Bayer AG - CardioVascular BioTherapeutics, Inc. - Celgene Corporation - CoDa Therapeutics, Inc. - CytoTools AG - Dipexium Pharmaceuticals LLC - EyeGene, Inc. - FirstString Research, Inc. - GlaxoSmithKline Plc - Human Stem Cells Institute - Innovaxis - Izun Pharmaceuticals Corporation - Karyopharm Therapeutics, Inc. - Lytix Biopharma AS - MediaPharma s.r.l. - MediWound Ltd. - NovaLead Pharma Pvt. Ltd. - Oneness Biotech Co., Ltd. - Osiris Therapeutics, Inc. - Plurogen Therapeutics, Inc. - Sanofi - Stratatech Corporation - TechnoPhage SA - TGV-Laboratories - Theravasc, Inc. - Tissue Med Biosciences - USV Limited For more information visit http://www.researchandmarkets.com/research/n9...betic_foot
DPRX: 10.39 (+0.07), OSIR: 5.47 (+0.27), MDWD: 8.03 (+0.06), GSK: 42.36 (+0.60), KPTI: 7.97 (+0.29), CELGZ: 1.45 (+0.01)
MediWound Ltd. Industry - Product Pipeline Review 2015 | Acute Market Reports
M2 - Tue Dec 22, 3:55AM CST
Acute Market Reports's, 'MediWound Ltd. - Product Pipeline Review - 2015', provides an overview of the MediWound Ltd.'s pharmaceutical research and development focus.
MDWD: 8.03 (+0.06)
Global Burns Therapeutics Pipeline Review 2015
M2 - Thu Dec 03, 7:57AM CST
Research and Markets (http://www.researchandmarkets.com/research/phkvtr/burns_pipeline) has announced the addition of the "Burns - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Burns, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Burns and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adocia - AlgiPharma AS - Biogenomics Limited - Birken AG - CytoTools AG - Destiny Pharma Limited - HanAll Biopharma Co., Ltd. - Kuros Biosurgery AG - MediWound Ltd. - Novan, Inc. - Novartis AG - Pherecydes Pharma SA - Phosphagenics Limited - Se-cure Pharmaceuticals Ltd. - Stratatech Corporation - USV Limited - Vida Therapeutics Inc. - Xiber Science GmbH For more information visit http://www.researchandmarkets.com/research/ph...s_pipeline
MDWD: 8.03 (+0.06), NVS: 80.49 (+0.78)
MediWound to Present at the Oppenheimer 26th Annual Healthcare Conference
GlobeNewswire - Tue Dec 01, 8:45AM CST
MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn and wound management, announces that Company management will participate at the Oppenheimer 26 Annual Healthcare Conference taking place from December 8-9 at the Westin Grand Central Hotel in New York City. Gal Cohen, President and Chief Executive Officer, will deliver MediWound's presentation on Tuesday, December 8 at 1:35 p.m. Eastern time.
MDWD: 8.03 (+0.06)
MediWound Appoints Aharon Yaari to Its Board of Directors
GlobeNewswire - Tue Dec 01, 6:00AM CST
MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn and wound management, announces today the appointment of Aharon Yaari to the Company's Board of Directors. With this change, the Company's Board of Directors increases to seven members, while the composition of the Board's committees remain unchanged.
MDWD: 8.03 (+0.06)
